Abstracts tagged "Demographics"

Abstract Number: 1832 • ACR Convergence 2025
Time-to-Event Analysis of Statin Use and Thrombotic Risk in Patients with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
Christine Lenchur¹, Niurka Liranzo Tejera¹, Adal Abonamah¹, Takemichi Matsui¹, Emily Cosentino¹, Priscilla Abate Namnum², Olga Marushchak¹, Melissa Akselrad¹, Martin John³, Sophia Lutgen⁴, Celestine He⁵, Boluwatito Oladeinde³, Harleen Sidhu⁶, Emilia Bagiella⁵, Ian Wright⁵ and Chrisanna Dobrowolski⁵, ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York City, NY, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine at Mount Sinai/NYC H+H- Elmhurst, Queens, NY, Rego Park, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) face elevated risk of thrombotic events (TEs) due to traditional cardiovascular factors and chronic inflammation. Statins may offer…
Abstract Number: 0393 • ACR Convergence 2025
Effects of Self-Reported Medication Barriers on Medication Adherence and Disease Activity in a Cohort of Patients with Juvenile Idiopathic Arthritis
Aditi Shaily¹, Allison R. Eckard², Paul Nietert³, Emily Vara¹, Natasha Ruth⁴ and Mileka Gilbert³, ¹Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ²Departments of InternDivision of Infectious Diseases, Medical University of South Carolina, Charleston, SC, ³Medical University of South Carolina, Charleston, SC, ⁴Medical University South Carolina, Charleston, SC
Background/Purpose: Medications used to manage juvenile idiopathic arthritis (JIA) are highly effective in preventing joint damage and provide a favorable prognosis. Many patients, however, struggle…
Abstract Number: 1554 • ACR Convergence 2025
Demographic, Clinical, and Mortality Trends in Scleroderma Patients with Gastric Antral Vascular Ectasia (GAVE): A National Inpatient Analysis
Akanksha Sharma¹, Veera Durga Vaishnavi Kurra² and Neev Mehta³, ¹UPMC Mercy hospital, Pittsburgh, PA, Pittsburgh, PA, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Lahey Hospital and Medical Center, Burlington, MA
Background/Purpose: Gastric antral vascular ectasia (GAVE), commonly known as “watermelon stomach,” is a rare but potentially severe gastrointestinal manifestation in systemic sclerosis (SSc). Despite its…
Abstract Number: 0269 • ACR Convergence 2025
Clinical Landscape and Severity Markers of VEXAS Syndrome in a Spanish Cohort: Findings from VEXASSER Study Group
Paula García-Escudero¹, Marta López², Berta Magallares³, Dolly Viviana Fiallo Suárez⁴, Diego Dios Santos⁵, César Antonio Egües Dubuc⁶, Santos Castañeda⁷, Alicia Garcia⁸, Isla Morante Bolado⁹, Elena María Oliver García¹⁰, Clara Garcia Belando¹¹, Cristina Corrales¹², Francisco Javier Toyos¹³, Judit Font-Urgelles¹⁴, Meritxell Salles Lizarzaburu¹⁵, Carolina Merino¹⁶, Irene Carrion¹⁷, Jose Angel Hernandez¹⁸, Lourdes Villalobos¹⁹, Alina-Lucica Boteanu²⁰, Beatriz Frade Sosa²¹, cristiana Sieiro²², Irene Monjo Henry²³, Ernesto Trallero²⁴, Eugenia Enriquez²⁵, Maria Rodriguez²⁶, Elena Riera Alonso²⁷, Marta Ibañez²⁸, Delia Reina²⁹, Rafael Benito Melero González³⁰, Giuliano Boselli³¹, Alberto Mariano³², Ignacio Vázquez Gómez³³, Jose Alberto Miranda³⁴, Clara Moriano³⁵, Elena Aurrecoechea³⁶, Paloma Vela Casasempere³⁷, Iñigo Rúa-Figueroa³⁸ and Jaime Calvo³⁹, ¹Hospital Universitario Álava, Bilbao, Spain, ²Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ³Hospital de Sant Pau, Bareclona, ⁴H.U. Doctor Negrín, Gran Canarias, ⁵C. H. U. A Coruña, A Coruña, Spain, ⁶Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁷Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁸Rheumatologist, La Laguna, Spain, ⁹Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, ¹⁰H.C. U. Lozano Blesa, Zaragoza, ¹¹H.C. U. Virgen de la arrizaca, Murcia, ¹²HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, Santander, Spain, ¹³Virgen Macarena University Hospital,, Sevilla, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁵Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, ¹⁶Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, ¹⁷Hospital del Mar, Barcelona, Spain, ¹⁸Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain, ¹⁹Ramon y Cajal Hospital, MADRID, Spain, ²⁰H.U. Ramón y Cajal, Madrid, Spain, ²¹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²²Univrsity of Manchester, Manchester, United Kingdom, ²³Hospital Universitario La Paz, Madrid, Spain, ²⁴H. U. Vall d'Hebron, Barcelona, ²⁵Clínica Universidad de Navarra, Madrid, Spain, ²⁶H. Clínico San Carlos, Madrid, Spain, ²⁷Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ²⁸Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ²⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ³⁰C. H. U. de Ourense, Ourense, ³¹Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ³²Virgen del Rocío University Hospital, Sevilla, Spain, ³³H.U. Doctor Peset, Valencia, ³⁴C. H. U. Lucus Augusti, Lugo, Spain, ³⁵Hospital León, LEON, Castilla y Leon, Spain, ³⁶H. Sierrallana, Santander, ³⁷Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ³⁸Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ³⁹Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain
Background/Purpose: VEXAS syndrome is a rare disease caused by somatic mutations in UBA1 gene. Different mutations in this gene appear to be associated with specific…
Abstract Number: 1513 • ACR Convergence 2025
Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
Ufuoma Mamoh¹, Queeneth Edwards², Chukwuemelie Okeke³, Justin Riley Lam⁴, Soziema Salia⁵ and Christhopher Haas⁶, ¹Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ²Georgia Southern University, Statesboro, GA, ³Maimonides Medical Center, Brooklyn, NY, ⁴Albert Einstein Medical Center, Philadelphia, PA, ⁵MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, MD, ⁶MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that disproportionately affects racial and ethnic minority populations, particularly Black/African American and Hispanic/Latino individuals. In…
Abstract Number: 0240 • ACR Convergence 2025
Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features
Amir Razmjou¹, Alexandra Klomhaus², David Kellner³, Meika Fang⁴, Michael Weisman⁵ and John FitzGerald³, ¹UCLA / Veterans Affairs, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA, Los Angeles, CA, ⁴VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁵Cedars-Sinai Medical Center, LOS ANGELES, CA
Background/Purpose: Behçet’s disease (BD) is a chronic systemic disease with heterogenous clinical presentations. The strongest genetic risk factor and diagnostic biomarker for BD is the…
Abstract Number: 1498 • ACR Convergence 2025
Both Race and Socioeconomic Status Affect Mortality in SLE
Gursimran Kaur¹, Daniel Goldman², Andrea Fava³, Laurence Magder⁴ and Michelle Petri², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: A recent meta-analysis found an overall 2.87-fold increase in all-cause mortality in systemic lupus erythematosus (SLE) with cause-specific increases in renal disease, infections, cardiovascular…
Abstract Number: 0179 • ACR Convergence 2025
Digital Divide in Rheumatology: Patterns of Technology and AI Adoption Across Generations of Specialists
CARLA F DIONELLO¹, ANA F PADUA², Claudia Marques³, BRUNA L PORTO⁴, LEONARDO R CAMPOS⁵, RODRIGO OLIVEIRA⁶, GUSTAVO GM BALBI⁷, RODRIGO LUPPINO-ASSAD⁶, YURE G AZEVEDO⁸, LUIZ F DIPE⁹, BRUNO BORDALLO⁵, Cleandro Pires¹⁰, Licia Maria Henrique da Mota¹⁰ and PAULA MONTINA¹⁰, ¹FEDERAL UNIVERSITY OF RIO DE JANEIRO - UFRJ, RIO DE JANEIRO, Rio de Janeiro, Brazil, ²SANTA CASA MG, BELO HORIZONTE, Minas Gerais, Brazil, ³Hospital das Clinicas - Universidade Federal de Pernambuco - UFPE, Recife, Pernambuco, Brazil, ⁴UNIVATES, SÃO LEOPOLDO, Rio Grande do Sul, Brazil, ⁵UFF, Rio de Janeiro, Rio de Janeiro, Brazil, ⁶FMRP-USP, Ribeirão Preto, Sao Paulo, Brazil, ⁷UFJF, JUIZ DE FORA, Minas Gerais, Brazil, ⁸SCR, SOBRAL, Ceara, Brazil, ⁹GRUPO AMIL, SÃO PAULO, Sao Paulo, Brazil, ¹⁰UNB, Brasilia, Distrito Federal, Brazil
Background/Purpose: The integration of digital tools and artificial intelligence (AI) in rheumatology practice has advanced rapidly. However, disparities in adoption across generations of specialists remain…
Abstract Number: 1452 • ACR Convergence 2025
Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
Nikolaos Kougkas¹, Konstantinos Tsafis², Dimitrios Deligeorgakis³, Vasileios Papadopoulos⁴, Nikolaos Fytanidis⁵, Michail Krikelis⁶, Evangelia Mole⁷, Sousana Gazi⁷, Nikolaos Koletsos⁸, EVRIPIDIS KALTSONOUDIS⁹, Paraskevi V Voulgari¹⁰, Anastasios Karamanakos¹¹, Maria Pappa¹², Maria Tektonidou¹³, Petros Sfikakis¹⁴, Kalliopi Klavdianou¹⁵, aggelos Banos¹⁶, Eleni Kalavri¹⁷, Konstantinos Kottas¹⁸, Gkikas Katsifis¹⁸, MARIA KONSTA¹⁹, Eleftheria Grika²⁰, Charalampos Sfontouris²⁰, Evgenia Mavrea²¹, Christos Koutsianas²², Evangelia Kataxaki²³, Eleni Sampatakaki²⁴, Konstantina Zoupidou²⁵, Pelagia Katsimpri²⁶, Alexios Iliopoulos²⁷, Georgios Iliopoulos²⁸, Dimitrios Daousis²⁹, Ilias Bournazos³⁰, DIMITRIOS KAROKIS³¹, Dimos Patrikos³², Theodoros Dimitroulas³, Dimitrios Vassilopoulos²¹, George E Fragoulis³³ and Charalampos Papagoras³⁴, ¹⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ²Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Thessaloniki, Greece, ³Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Greece, ⁴Department of Medicine Democritus University of Thrace, Laboratory of Anatomy, Alexandroupolis, Greece, Alexandroupolis, Evros, Greece, ⁵University Hospital of Alexandroupolis, Democritus University of Thrace, First Department of Internal Medicine, Alexandroupolis, Greece, Alexandroupolis, Greece, ⁶KAT Hospital, Athens, Department of Rheumatology, Athens, Greece,, Athens, Attiki, Greece, ⁷Rheumatology department, KAT General Hospital of Attica, Athens, Attiki, Greece, ⁸School of Health Sciences, Faculty of Medicine, University of Ioannina, Department of Rheumatology, Ioannina, Greece, Ioannina, Ioannina, Greece, ⁹Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ¹⁰Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece, ¹¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Laiko”, First Department of Propedeutic and Internal Medicine, Athens, Greece, Athens, Greece, ¹²Rheumatology and Clinical Immunology Unit, ⁴th Department of Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ¹³National and Kapodistrian University of Athens, Athens, Greece, ¹⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ¹⁵Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Kaisariani Athens, Greece, ¹⁶Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Athens, Attiki, Greece, ¹⁷"Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Athens, Greece, ¹⁸Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, Athens, Greece, ¹⁹Sismanoglion Hospital, Athens, Greece, Marousi, Attiki, Greece, ²⁰Evaggelismos Athens General Hospital, Department of Rheumatology, Athens, Greece, Athens, Greece, ²¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Clinical Immunology-Rheumatology Unit, ²nd Department of Medicine and Laboratory, Athens, Greece, Athens, Greece, ²²Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Athens, Greece, ²³General Hospital Elefsinas Thriaseio,Attica, Rheumatology Department, Athens, Greece, Athens, Greece, ²⁴Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Attiki, Greece, ²⁵Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Greece, ²⁶Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ²⁷⁴¹⁷ Army Share Fund Hospital (NIMTS), Department of Rheumatology, Athens, Greece, ZOGRAFOU, Greece, ²⁸Patras University Hospital, University of Patras Medical School, Department of Rheumatology, Patras, Greece, Patras, Akhaia, Greece, ²⁹Patras University Hospital, University of Patras Medical School, Department of Rheumatology, Patras, Greece, Patra, Greece, ³⁰Private practice, Athens, Greece, Athens, Greece, ³¹Private practice, Patras, Greece, Patras, Greece, ³²Private practice, Athens, Greece, Ag. Paraskevi, Greece, ³³First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ³⁴First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease that significantly impairs quality of life. Although biologic and targeted synthetic DMARDs (b/tsDMARDs) have improved disease…
Abstract Number: 1394 • ACR Convergence 2025
Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic disorder characterized by exocrine gland inflammation, leading to dry eyes/mouth, and multiple organ systems involvement1. The European League…
Abstract Number: 1393 • ACR Convergence 2025
Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition characterized by diverse clinical manifestations, which often complicates diagnosis and disease management1. Previous epidemiological estimates of…
Abstract Number: 1263 • ACR Convergence 2025
Health Literacy diversity among rheumatology patients: insights from a tertiary rheumatology centre
Cristina Calomarde-Gomez¹, Mrinalini Dey², Chris Wincup³, María Alonso de Francisco⁴, Christina Cheng⁵, Richard Osborne⁵ and Elena Nikiphorou⁶, ¹Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³King's College Hospital, London, United Kingdom, ⁴H. U. Puerta de Hierro Majadahonda, Tres Cantos, Spain, ⁵La Trobe University, Melbourne, Victoria, Australia, ⁶King's College London, London, United Kingdom
Background/Purpose: Health literacy is a potential social determinant of health, fundamental to patient engagement, clinical communication, and long-term outcomes of disease. Understanding health literacy at…
Abstract Number: 1153 • ACR Convergence 2025
New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Michael Cargill² and Gurjit Kaeley³, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: The novel diagnosis of VEXAS in 2020 led to the proposed possibility of a new category of hematoinflammatory syndromes linking clinically overlapping hematologic and…
Abstract Number: 2666 • ACR Convergence 2025
Rare TNFAIP3 Hypomorphic Variants are a Massively Underestimated Driver of Human Autoinflammatory Disease
Danica Lee¹, Urekha Karri², Yiming Luo³, Kader Cetin Gedik⁴, Manuel Carpio Tumba⁵, Prabal Chhibbar⁶, Priyamvada Roy⁶, Guido Falduto⁷, Jishnu Das⁵ and Daniella Schwartz⁵, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²School of public health, Pittsburgh, PA, ³Columbia University, New York, NY, ⁴UPMC Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, ⁷University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: TNFAIP3 encodes the ubiquitin editing enzyme A20, which inhibits multiple proinflammatory signaling pathways. Heterozygous germline mutations in TNFAIP3 cause the autoinflammatory disease Haploinsufficiency of…
Abstract Number: 1071 • ACR Convergence 2025
Depression and Mental Health Service Gaps in Autoimmune Disease: Insights from a Simulated BRFSS Dataset
Malay Rathod¹, Shivani Modi², Veera Durga Vaishnavi Kurra³, Karan Yagnik⁴ and Doantrnag Du⁴, ¹Monmouth Medical Center, Ewing, NJ, ²Jefferson Einstein Montgomery Hospital, Ewign, NJ, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Monmouth Medical Center, Long Branch, NJ
Background/Purpose: Autoimmune diseases are complex conditions that may predispose individuals to an increased mental health burden, including depression. The immune system leads to inflammation in…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].